Chiltern Capital has invested in Surepharm, a contract development manufacturing organisation servicing the pharmaceutical market. Carter Schwartz’s, Lewis Buckley, advised on the management team hires.
Surepharm provides outsourced formulation, development, manufacturing, and packaging of products for its customers in the UK and overseas. It currently specialises in producing solid dose tablets and capsules, including niche medicines, controlled drugs, and veterinary products.
Chiltern’s investment will support Surepharm as it enhances its formulation and development offering, as well as provides funding for new dosage forms.
Alongside investments in sales and marketing, the funding will enable Surepharm to provide customers with an end-to-end service, from drug development through to a packaged commercial product, across a range of product types.
Joe Bennett, Chiltern Capital, said: “Through our research and direct origination team, we had been targeting a platform investment in the pharmaceutical sector and Surepharm gives us a strong market entry point. We have built an ambitious management team of sector experts, and are looking forward to delivering the plan through a combination of organic investment and complimentary M&A.”
Article from Real Deals and official Chiltern Capital press release.
Head of Communications
M: +44(0)7399 448 885
About Carter Schwartz
Carter Schwartz is one of the UK’s leading executive search boutiques providing an innovative range of human capital solutions for the Independent Health and Social Care, Education, Med-Tech and Life Science markets. With an impressive global reach through offices in the UK, USA and Germany, their track record of leadership appointments places them at the forefront of your growth plans when it comes to your next C-Suite, or non-executive leadership hires.
+44 (0)203 102 4835 | firstname.lastname@example.org | carterschwartz.co.uk